It is generally accepted that intracellular oxidative stress induced by proteasome inhibitors is a byproduct of endoplasmic reticulum (ER) stress. Here we report a mechanism underlying the ability of proteasome inhibitors bortezomib (BTZ) and carfilzomib (CFZ) to directly induce oxidative and ER stresses in multiple myeloma (MM) cells via transcriptional repression of a gene encoding mitochondrial thioredoxin reductase (TXNRD2). TXNRD2 is critical for maintenance of intracellular red-ox status and detoxification of reactive oxygen species. Depletion of TXNRD2 to the levels detected in BTZ-or CFZ-treated cells causes oxidative stress, ER stress and death similar to those induced by proteasome inhibitors. Reciprocally, restoration of near-wildtype TXNRD2 amounts in MM cells treated with proteasome inhibitors reduces oxidative stress, ER stress and cell death by~46%,~35% and~50%, respectively, compared with cells with unrestored TXNRD2 levels. Moreover, cells from three MM cell lines selected for resistance to BTZ demonstrate elevated levels of TXNRD2, indirectly confirming its functional role in BTZ resistance. Accordingly, ectopic expression of TXNRD2 in MM cell xenografts in immunocompromised mice blunts therapeutic effects of BTZ. Our data identify TXNRD2 as a potentially clinically relevant target, inhibition of which is critical for proteasome inhibitor-dependent cytotoxicity, oxidative stress and ER stress.
INTRODUCTION
Multiple myeloma (MM) is a malignancy of plasma cells that accounts for 410% of all hematological cancers.
1,2 Although introduction of novel agents has substantially increased the median overall survival of myeloma patients, the disease still remains incurable. [3] [4] [5] One of these agents, boretezomib (BTZ), is a first-in-class proteasome inhibitor that delivered a major breakthrough in MM treatment. [1] [2] [3] [4] [5] BTZ is a dipeptide that reversibly binds to and inhibits the activity of the 20S proteasome. [3] [4] [5] Recently, the FDA approved the only other proteasome inhibitor, carfilzomib (CFZ), available for MM patients that are refractory to other types of therapy including BTZ. 6 Unlike BTZ, CFZ binds irreversibly and produces a more sustained inhibition of the 20S proteasome than the one achieved with BTZ. [7] [8] [9] Although the molecular mechanisms of BTZ and CFZ cytotoxicity appear to be very similar, CFZ induces death in MM cells more potently than BTZ. [7] [8] [9] Inhibition of proteasome activity leads to accumulation of unfolded proteins that causes endoplasmic reticulum (ER) stress. 10 If unresolved, the ER stress induces cell death via several pathways including transcriptional activation and repression of pro-and anti-apoptotic genes, respectively. 10, 11 Therefore, the ER stress is considered as one of the major determinants of the proteasome inhibitor cytotoxicity. 10, 11 Overproduction of intracellular reactive oxygen species (ROS) over antioxidant molecules causes oxidative stress. 12 Cancer cells often undergo oxidative stress due to oncogene activation and/or increased metabolic activity, 13 and it is generally accepted that normal cells produce less ROS than their transformed counterparts. [13] [14] [15] Accordingly, transformed cells are more vulnerable to oxidative stress-inducing agents than normal cells. 13, 15 Oxidative stress has been characterized as an important mediator of BTZ toxicity in cells from several solid malignancies 16, 17 and mantle cell lymphoma, where markers of oxidative stress can serve as an indicator of clinical outcome. 18 On the other hand, oxidative stress has been largely considered a consequence of BTZ-induced ER stress. [19] [20] [21] The possibility that induction of oxidative stress independently from the ER stress represents the major component of proteasome inhibitor cytotoxicity has never been addressed.
Recently, we reported that BTZ causes death in MM cells in part via epigenetic upregulation of the Kruppel-like transcription factor 9 (KLF9). 22 Also, we demonstrated that KLF9 increases intracellular ROS levels in normal human and mouse fibroblasts via transcriptional repression of several genes participating in ROS metabolism, including the gene for mitochondrial thioredoxin reductase (TXNRD2). 23 In addition to TXNRD2, the TXNRD protein family includes ubiquitously expressed cytoplasmic TXNRD1, 24 and testisspecific TXNRD3. 24 These proteins are selenocysteine-containing enzymes that reduce oxidized thioredoxins and several other proteins, 24 thus upholding intracellular red-ox status. 24 In particular, TXNRD2 is critical for ROS scavenging in mitochondria. 24, 25 The functional involvement of TXNRD2 or other ROS-metabolizing enzymes in the BTZ-or CFZ-induced ER stress and/or cell death is unknown. In answer to this question, here we present data demonstrating the central role of TXNRD2 in modulation of BTZ-dependent oxidative stress, ER stress and cell death in MM cells in vitro and of therapeutic effects of BTZ in a preclinical mouse model of MM.
MATERIALS AND METHODS

Cell lines and reagents
MM cells MM1.S and RPMI-8226 (purchased from ATCC) were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 units/ml penicillin G +100 μg/ml streptomycin, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate. The following cell lines were a kind gift from Dr Robert Orlowski (MD Anderson Cancer Center): ANBL-6wt, ANBL-6BR, KAS-6wt KAS-6BR, RPMI-8226wt and RPMI-8226BR. Cells were maintained as described previously. 8, 26 Briefly, bortezomib-resistant (BR) cells were propagated in growth media supplemented twice per week with 10 nM BTZ. Before experiments, the cells were removed from drug-supplemented media for at least 72 h. All cell culture reagents were purchased from Invitrogen (Carlsbad, CA, USA). BTZ was purchased from LC Laboratories (Woburn, MA, USA), carfilzomib was purchased from Selleckchem (Houston, TX, USA). Cell lines have been recently authenticated and verified for being mycoplasma-free using MycoAlert mycoplasma detection Kit purchased from Lonza (USA, Cat no. LT07-318).
Animals
All experiments involving animals were approved by the institutional Animal Care and Use Committee. The MM cell xenograft model has been described previously. 27 Briefly, 6-8 week old, female severe combined immunodeficiency (SCID) mice (Strain: C.B-Igh-1bIcrTac-Prkdcscid/Ros) (n = 7 per group) were inoculated subcutaneously with MM1.S cells expressing either an empty vector or TXNRD2 complementary DNA (cDNA) (5 × 10 6 cells per injection). When tumor volumes reached 100 mm 3 , mice with similarly increasing tumor burden were randomized into two subgroups and treated intravenously with either vehicle (0.5% dimethyl sulfoxide in phosphate-buffered saline) or 0.5 mg/kg BTZ dissolved in vehicle, twice weekly on days 1 and 4 for~2 weeks. Tumor size was measured using calipers every other day and tumor volume was calculated using the following formula: V = 0.5 × length (mm) × length (mm) × width (mm). Mice were killed when tumor volume reached 2 cm 3 or when a tumor became ulcerated. No animals were excluded from the study as all animals developed palpable tumors~100 mm 3 , 2-3 weeks post subcutaneous inoculation of MM1.S cells. After the randomized allocation of mice into two groups, the animals and treatments were coded to 'blind' the investigator until the experiment reached its endpoint.
Lentiviral constructs and infection
For overexpression experiments, human KLF9 cDNAs were cloned under the control of the cytomegalovirus promoter into the lentiviral vectors pLV-SV40-puro (a gift from Dr Peter Chumakov, Cleveland Clinic). The TXNRD2 cDNA including the portion of 3′ UTR containing the conserved C-terminal selenocysteine residue 28 was amplified using the following primers; forward (5′-ACACATCTAGACCCACGACGATGGCGGCAATG-3′) and reverse (5′-AGTCTCTCGAGCGGACATGGGTGCCCACAGGG-3′). The pLKO-1 lentiviral vectors containing control shRNA and shRNAs for KLF9, NOXA and TXNRD2 were purchased from Sigma-Aldrich. Human KLF9: TRCN0000013632 and TRCN0000013628; Human TXNRD2: TRCN0000046473 and TRCN0000046474; The lentiviral infection protocol has been described previously. 29 Equivalent amounts of control virus were used in all experiments.
Quantitative reverse transcription real-time PCR Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was prepared using the cDNA reverse transcription kit (Invitrogen). Quantitative reverse transcription real-time PCR was performed on 7900HT fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) using either Taqman Universal Master Mix II (Applied Biosystems) or SYBR Green PCR Master Mix (Applied Biosystems). The following Taqman probes were used: Human β-actin: Hs99999903_m1, Human KLF9: Hs00230918_m1 and Human TXNRD2: Hs01561341_m1. The following PCR primers were used: Human CHOP: (5′-AGAACCAGGAAACGGAAACAGA-3′) and (5′-TCTCCTTCATGCGCTGCTTT-3′) and human XBP1s: (5′-GAGTCCGCAGCAGGTG-3′) and (5′-GTGTCAGAGTCC ATGGGA-3′). PCR data were analyzed using the sequence detection software (SDS) 2.4 (Applied Biosystems).
Immunoblotting
The following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were used: KLF9 (sc-12996 and sc-12994), TXNRD2 (sc-46279), ATF4 (sc-200), and tubulin (sc-8035). Membranes were developed using alkaline phosphatase-conjugated secondary antibodies and Pierce Fast Western Blot Kit (Thermo Scientific, Rockford, IL, USA), and the Alpha-Innotech FluorChem HD2 imaging system (Alpha Innotech, San Leandro, CA, USA). For the detection of endogenous NOXA levels, Pierce SuperSignal West Femto Substrate (Thermo Scientific) was used. The ImageQuant 2.0 program package (Molecular Dynamics, Sunnyvale, CA, USA) was used for signal quantification. An equivalent area in each lane was used to determine the background signal and this was subtracted from the value of the protein signal in that lane.
Detection of ROS
Approximately 3 × 10 5 cells were collected, washed with phosphatebuffered saline and resuspended in 300 μl of Dulbecco's-phosphatebuffered salinesolution containing 5 μg/ml of CMH2DFCDA (InvitrogenCatalog no. C6827) according to the manufactures instructions. Cells were incubated at 37°C for 30 min with gentle shaking every 5 min to prevent cells from settling at the bottom. Cells were pelleted at 1000 r.p.m. for 5 min. Fluorescence was measured via flow cytometry (Ex/Em:~492-495/517-527 nm) using LSRIIA (BECTON DICKINSON). Detection was based on mean fluorescence intensity of at least 10 000 cells.
Trypan blue exclusion assay
An aliquot of cell suspension was mixed 1:1 with Trypan Blue Stain (NutriCyte, Cat no. 02-0108-0100) and incubated for 2 min at room temperature. Total viable (white cells) and nonviable (blue cells) were counted with a hemocytometer under the microscope.
Chromatin immunoprecipitation
Interactions between KLF9 and the TXNRD2 promoter were assessed using the EZ-Chip kit from Millipore according to the manufacturer's recommendations with the following antibodies from Santa Cruz Biotechnology: normal goat IgG (sc-2755), KLF9 (sc-12996). The following primers were used for the analysis of KLF9 binding to the DNA: GAPDH promoter (5′-TACTAGCGGTTTTACGGGCG-3′) and (5′-TCGAACAGGAGCAGAGAGCGA -3′); TXNRD2 promoter region (5′-AACCCTCCCTTCCCAGTTTTG-3′), (5′-AAAA AGCTGGCTCCATGCTG-3′).
Statistical analysis
For animal studies, sample size was determined as a function of effect size ((difference in means)/(s.d.) = 2.0) for two sample t-test comparison assuming a significance level of 5%, a power of 90% and a two-sided t-test, as described previously. 30 Each experiment was reproduced at least two times with consistent results. A two-tailed P-value o0.05 was considered statistically significant for all analyzes.Data was analyzed using parametric statistical methods such as t-test for one or two group comparisons or analysis of variance for several groups. Normal distribution was confirmed using normal probability plot (GraphPad Prism 6.0, GraphPad Software, San Diego, CA, USA), variance was also assessed using GraphPad Prism 6.0 both within and between groups and were approximately the same.
RESULTS
Proteasome inhibitors downregulate TXNRD2 and generate oxidative stress before induction of cell death To determine the temporal relationship between oxidative stress and cell death in MM cells undergoing proteasome inhibition, we focused on BTZ, a widely used anti-MM agent. In addition, to control for BTZ-nonspecific effects, we included the only FDAapproved BTZ analog, CFZ. MM1.S and RPMI-8226 cells were incubated with increasing doses of each drug followed by measurement of ROS and cell death in each cell population. The levels of ROS were upregulated by either agent already at 24-h post treatment ( Figure 1a ) without any significant increase in cell death, which occurred~48 -h post treatment (Figure 1b) as was reported earlier. 22 Thus, BTZ and CFZ generate oxidative stress before affecting cell viability.
Recently, we have demonstrated that KLF9 transcriptionally represses TXNRD2 in normal human and mouse fibroblasts. 23 We were interested in whether BTZ or CFZ also repress TXNRD2 levels in MM cells. Treatment of MM1.S and RPMI-8226 cells with either agent induced mRNA and protein levels of KLF9 and decreased TXNRD2 mRNA and protein levels by 24-h post treatment (Figures 1c and d) .
To determine whether repression of TXNRD2 by BTZ or CFZ is associated with an increased occupancy of its promoter by KLF9, we performed chromatin immunoprecipitation with control (normal goat IgG) or KLF9-specific goat antibodies from untreated MM1.S cells or cells treated for 24 h with the amounts of BTZ or CFZ that produce equivalent suppression of TXNRD2 (10 or 5 nM, respectively). Following precipitation, the chromatin was de-cross-linked and the purified DNA was probed in quantitative PCR with primers corresponding to the human TXNRD2 promoter. As a negative control, we used PCR primers corresponding to a KLF9-irrelevant promoter (GAPDH). As shown in Figure 1e , a significant enrichment of TXNRD2 promoter-specific DNA was detected in chromatin material precipitated with KLF9-specific but not control antibodies from the cells treated with BTZ or CFZ compared with untreated cells.
To determine whether BTZ or CFZ induce ROS via a KLF9-dependent mechanism, we knocked-down KLF9 in MM1.S and RPMI-8226 cells using lentivirus-based shRNAs ( Figure 2a) . As expected, the TXNRD2 mRNA and protein levels were increased by KLF9 depletion (Figures 2a and b) . 48-h post infection, MM1.S and RPMI-8226 cells were treated with different doses of BTZ or CFZ for 24 or 48 h. KLF9-depleted cells demonstrated a substantial decrease in the levels of BTZ-or CFZ-induced ROS (24-h post treatment) and 50% drop in cell death (48-h post treatment) compared with the cells transduced with control shRNA (Figures 2c and d) .
To assess the relative input of PI-induced ROS into overall cell death caused by these PI, we performed experiment described in Taken together, these data demonstrate that BTZ and CFZ cause elevation of ROS in KLF9-dependent manner concomitantly with suppression of TXNRD2 before the induction of cell death.
TXNRD2 reduces oxidative stress, ER stress and apoptosis induced by proteasome inhibitors To identify the functional role of TXNRD2 in the induction of oxidative stress and cell death caused by BTZ or CFZ, we transduced MM1.S and RPMI-8226 cells with a control lentiviral vector or a lentiviral vector containing TXNRD2 cDNA (including a portion of the 3′UTR for proper incorporation of selenocysteine (see Materials and Methods)). As a result, we generated MM cells expressing approximately two-to three-fold higher amounts of TXNRD2 than control populations (Figure 3a) . Four days post infection, the obtained cell populations were treated with 10 nM BTZ or 5 nM CFZ followed by measurements of ROS levels and cell death 24-and 48-h post treatment, respectively. Overexpression of TXNRD2 overcame PI-induced suppression of endogenous TXNRD2 levels (Figure 3a) , substantially decreased oxidative stress (Figure 3b ) and reduced cell death by~50% (Figure 3c) . ER stress has been reported to generate oxidative stress. 19, 20 Reciprocally, oxidative stress may cause ER stress. 11, 20 Thus, we were interested in whether PI-treated TXNRD2-overexpressing cells would demonstrate lower levels of ER stress markers than treated vector cells. As shown in Figures 3a and d , in response to PIs, MM cells overexpressing TXNRD2 demonstrated lower expression levels of several canonical markers of ER stress (ATF4, XBP1s and CHOP) 11 compared with the vector cells. Therefore, restoration of TXNRD2 levels in PI-treated MM cells decreases both oxidative stress and ER stress ultimately resulting in reduced cytotoxicity of PIs. These results suggest that upregulation of TXNRD2 may underlie one of the mechanisms of MM cell resistance to BTZ. To test this notion, we assessed the amounts of TXNRD2 in cells from previously described MM cell lines selected for resistance to BTZ and in their unselected counterparts (ANBL-6BR and ANBL-6wt; KAS-6BR and KAS-6wt; RPMI-8226BR and RPMI-8226wt, respectively). 8, 26 Levels of TXNRD2 were 1.9-3 fold higher in resistant cell lines compared with their unselected counterparts (Figure 3e) , indirectly attesting to the importance of TXNRD2 for MM cell resistance to BTZ.
TXNRD2 depletion mimics cytotoxic effects of proteasome inhibitors in MM cells
We hypothesized that the PI-induced decrease in TXNRD2 levels is one of the major causes of the PI cytotoxicity. To test this hypothesis, we depleted TXNRD2 in MM1.S and RPMI-8226 cells independently via two specific shRNAs approximately to the levels detected in BTZ-or CFZ-treated MM cells (Figure 4a ). Partial depletion of TXNRD2 substantially increased ROS levels and the levels of the ER stress markers 3 days post infection (Figures 4a-c) . In addition, depletion of TXNRD2 led to cell death 4-6 days post infection. The cytotoxicity caused by TXNRD2 depletion was largely due to induction of oxidative stress as was determined by reduction of cell death in TXNRD2-depleted cell populations incubated with the radical scavenger N-acetyl cysteine (Figures 4d  and e) . We concluded that partial depletion of TXNRD2 causes cytotoxic effects lower in scale but similar in nature to those induced by BTZ or CFZ in MM cells. Taken together, our data suggest that suppression of TXNRD2 is a novel mechanism of PI cytotoxicity.
TXNRD2 overexpression provides MM cell xenografts resistance to BTZ To evaluate the ability of TXNRD2 to increase resistance of MM cells to BTZ in vivo, we used a MM xenograft mouse model. To this end, MM.1S cells transduced with an empty lentiviral vector or a vector encoding TXNRD2 cDNA, as shown in Figure 3a , were 
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Cell number subcutaneously injected into SCID mice (5 × 10 6 cells per injection). When the tumor volumes reached~100 mm 3 (2-3 weeks post inoculation), mice in each group demonstrating similar tumor burden were randomly divided into two subgroups and treated intravenously with either vehicle (0.5% dimethyl sulfoxide in phosphate-buffered saline) or BTZ (0.5 mg/kg dissolved in the vehicle) twice weekly for 15 days according to the published protocols. 27 Treatment with BTZ substantially (by~43%) decreased tumor volume of MM1.S-vector xenografts compared with the vehicle-treated MM1.S-vector xenografts (Figures 5a, P o 0.001) . In contrast, BTZ treatment decreased the average volume of MM1.S-TXNRD2 xenografts only by~16% compared with MM1.S-TXNRD2 xenografts treated with the vehicle (Figures 5a, P o 0.001) . Representative pictures of vector or TXNRD2-expressing MM1.S xenografts excised at the end of the experiment are shown in Figure 5b . Thus, ectopic expression of TXNRD2 causes resistance of MM cell xenografts to BTZ treatment.
DISCUSSION
The anti-myeloma agent BTZ (Velcade, Millennium Pharmaceuticals, Cambridge, MA, USA) 1 and its second generation analog CFZ (Kyprolis, Onyx Pharmaceuticals, San Francisco, CA, USA) 8,9 act as proteasome inhibitors. As a result, PIs cause accumulation of unfolded proteins and ER stress which activates ER stress response (or unfolded protein response) to decrease the amounts of unfolded proteins. However, prolonged ER stress results in activation of several pro-death signaling pathways. 11 In addition, BTZ causes upregulation of several transcription factors independently of the ER stress at transcriptional (JUN, EGR1 and KLF9), 22, 31, 32 or post translational (NF-kB, MYC) 33,34 levels. Activation of these transcriptional regulators ultimately results in alteration in expression of pro-or anti-apoptotic genes. 22, [31] [32] [33] [34] Oxidative stress has been shown to have an important role in BTZ cytotoxicity in cells from several non-MM malignances, [16] [17] [18] [19] [20] although it is generally considered as a side effect of other processes associated with the ER stress. 11, 19 These processes include increased activity of the ER oxidoreductases, 11 depletion of the glutathione pool 11 or increased release of Ca 2+ from the ER.
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The functional role of ROS-metabolizing enzymes in cytotoxicity of BTZ or CFZ is not well-understood. Our data argue that increase in ROS levels via transcriptional repression of the ROS-detoxifying enzyme TXNRD2 has a prominent role in mediation of PI-induced ER stress and cell death. Indeed, near wildtype restoration of TXNRD2 levels prevents full scale PI-dependent induction of ROS, ER stress markers and death in MM cells (Figure 3 ). On the other hand, ectopic expression of TXNRD2 (or depletion of KLF9) did not affect the basal levels of ROS in MM cells. Similar findings have been reported by us earlier in different cell types. 23 As intracellular ROS are tightly regulated at multiple levels, it is conceivable that compensatory endogenous mechanisms would reconstitute the normal ROS levels if indeed ROS are downregulated due to TXNRD2 overexpression. On the other hand, under conditions of extreme oxidative stress caused by PIs, endogenous mechanisms responsible for maintenance of normal ROS levels are overwhelmed, and additional amounts of TXNRD2 become important for suppression of excessive ROS.
Overexpression of TXNRD2 in MM cells suppresses BTZ-induced cell death more efficiently than BTZ-dependent xenograft growth retardation in SCID mice. This is not surprising, as similar discrepancies have been widely described before, 34 including a report investigating cytotoxicity and efficacy of BTZ. 35 These discrepancies are usually attributed to the in vivo drug metabolism, pharmacokinetics and bioavailability, difference in proliferation rates of tumor cells in vitro and in xenografts and tumor microenvironment which may modulate the rates of drug-induced cell death. 34 Conversely, shRNA-mediated depletion of TXNRD2 to the levels detected in PI-treated MM cells is sufficient for the induction of oxidative stress and ER stress culminating in cell death at later time points (Figure 4 ). These data demonstrate that TXNRD2 downregulation is one of the causes of the ER stress in PI-treated MM cells. Our findings are supported by several publications demonstrating that the ER stress can be induced by oxidative stress-generating agents. [36] [37] [38] Our previous study 22 implicated KLF9 in cytotoxicity of BTZ and panobinostat, an experimental anti-histone deacetylase agent. 39 Recently, KLF9 was reported to decreases resistance of prostate cancer cells to flutamide, an agonist of the androgen receptor 40 Cumulatively, these reports suggest that KLF9 is a promising anticancer target, however, no known agents that can be used in cancer therapy specifically upregulate KLF9.
At the same time, the importance of KLF9 target TXNRD2 for mitochondrial and cellular red-ox homeostasis and cell viability has been demonstrated by several groups including ours in non-MM cells. [23] [24] [25] An inhibitor of all TXNRD enzymes, a gold-containing compound auranofin, has been recently demonstrated to induce death in MM cells. 41 Furthermore, BTZ cytotoxicity can be enhanced by small molecule inhibitors of the enzymes indirectly regulating ROS levels in MM cells. 30 Taken together these reports and our data argue that induction of oxidative stress, including inhibition of TXNRD2, is a viable anti-MM strategy. In summary, our data identify a novel mechanism underlying PI-dependent induction of oxidative and ER stresses in MM cells and a new functional PI target that can be exploited in the clinic for treatment of MM.
